☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
cervical cancer
Disease of the Month: Cervical Cancer
January 12, 2023
Agenus Reports the Withdrawal of BLA for Balstilimab to Treat Cervical Cancer
October 25, 2021
Merck's Keytruda (pembrolizumab) Receives the US FDA's Approval for Second Indication in Cervical Cancer
October 14, 2021
Seagen and Genmab's Tivdak (tisotumab vedotin-tftv) Receive the US FDA's Accelerated Approval for the Treatment of Recurrent or Me...
September 22, 2021
Merck Reports Results of Keytruda (pembrolizumab) in P-III KEYNOTE-826 Trial as 1L Treatment for Cervical Cancer
September 20, 2021
Regeneron and Sanofi Present Positive Results of Libtayo (cemiplimab) from P-III Trial for Cervical Cancer at ESMO2021
May 13, 2021
Merck Reports Results from the P-III (KEYNOTE-A18) Study of Keytruda for the Treatment of Cervical Cancer
March 15, 2024
Hologic’s Genius Digital Diagnostics System Receives the US FDA’s Clearance to Identify Pre-Cancerous Lesions
February 2, 2024
AstraZeneca and Daiichi Sankyo Reports sBLA Acceptance with Priority Review by the US FDA for Enhertu to Treat HER2-Expressing Sol...
January 30, 2024
Merck Reports US FDA’s Approval of Keytruda + Chemoradiotherapy for Treating FIGO 2014 Stage III-IVA Cervical Cancer
January 15, 2024
Qvin’s Q-Pad Kit Receives the US FDA’s Approval as a Step to Revolutionize Women’s Health with Menstrual Sample Testing
January 10, 2024
Pfizer’s sBLA for Tivdak Receives the US FDA’s Acceptance for Priority Review to Treat Cervical Cancer
January 10, 2024
Load more...
Back to Home
Modal title
×
Modal body text goes here.